210 related articles for article (PubMed ID: 34907588)
81. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.
Wieten E; Schreuders EH; Grobbee EJ; Nieboer D; Bramer WM; Lansdorp-Vogelaar I; Bruno MJ; Kuipers EJ; Spaander MCW
Gut; 2019 May; 68(5):873-881. PubMed ID: 29934436
[TBL] [Abstract][Full Text] [Related]
82. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States.
Singal AG; Corley DA; Kamineni A; Garcia M; Zheng Y; Doria-Rose PV; Quinn VP; Jensen CD; Chubak J; Tiro J; Doubeni CA; Ghai NR; Skinner CS; Wernli K; Halm EA
Am J Gastroenterol; 2018 May; 113(5):746-754. PubMed ID: 29487413
[TBL] [Abstract][Full Text] [Related]
83. Changes in colorectal cancer screening use after introduction of alternative screening offer in Germany: Prospective cohort study.
Guo F; Chen C; Schöttker B; Holleczek B; Hoffmeister M; Brenner H
Int J Cancer; 2020 May; 146(9):2423-2432. PubMed ID: 31291471
[TBL] [Abstract][Full Text] [Related]
84. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis.
Zhong GC; Sun WP; Wan L; Hu JJ; Hao FB
Gastrointest Endosc; 2020 Mar; 91(3):684-697.e15. PubMed ID: 31790657
[TBL] [Abstract][Full Text] [Related]
85. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy.
Winawer SJ; Flehinger BJ; Schottenfeld D; Miller DG
J Natl Cancer Inst; 1993 Aug; 85(16):1311-8. PubMed ID: 8340943
[TBL] [Abstract][Full Text] [Related]
86. Randomized Trial of Facilitated Adherence to Screening Colonoscopy vs Sequential Fecal-Based Blood Test.
Zauber AG; Winawer SJ; O'Brien MJ; Mills GM; Allen JI; Feld AD; Jordan PA; Fleisher M; Orlow I; Meester RGS; Lansdorp-Vogelaar I; Rutter CM; Knudsen AB; Mandelson M; Shaukat A; Mendelsohn RB; Hahn AI; Lobaugh SM; Soto Palmer B; Serrano V; Kumar JR; Fischer SE; Chen JC; Bayuga-Miller S; Kuk D; O'Connell K; Church TR
Gastroenterology; 2023 Jul; 165(1):252-266. PubMed ID: 36948424
[TBL] [Abstract][Full Text] [Related]
87. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies.
Brenner H; Stock C; Hoffmeister M
BMJ; 2014 Apr; 348():g2467. PubMed ID: 24922745
[TBL] [Abstract][Full Text] [Related]
88. Incremental benefits of screening colonoscopy over sigmoidoscopy in average-risk populations: a model-driven analysis.
Jeon J; Meza R; Hazelton WD; Renehan AG; Luebeck EG
Cancer Causes Control; 2015 Jun; 26(6):859-70. PubMed ID: 25783458
[TBL] [Abstract][Full Text] [Related]
89. Cost effectiveness and projected national impact of colorectal cancer screening in France.
Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
[TBL] [Abstract][Full Text] [Related]
90. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
Brenner H; Tao S
Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
[TBL] [Abstract][Full Text] [Related]
91. Contribution of the OC Sensor
Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
[TBL] [Abstract][Full Text] [Related]
92. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
Lieberman DA; Weiss DG;
N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
[TBL] [Abstract][Full Text] [Related]
93. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
94. Gastrointestinal Conditions: Colorectal Cancer Screening and Prevention.
Davis J; Kellerman R
FP Essent; 2022 May; 516():17-22. PubMed ID: 35507309
[TBL] [Abstract][Full Text] [Related]
95. Comparative effectiveness of screening strategies for colorectal cancer.
Barzi A; Lenz HJ; Quinn DI; Sadeghi S
Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
[TBL] [Abstract][Full Text] [Related]
96. Performance of the Asia-Pacific Colorectal Screening score in stratifying the risk of advanced colorectal neoplasia: A meta-analysis and systematic review.
Luu MN; Trinh NA; Tran TLT; Dang TP; Hiyama T; Quach DT
J Gastroenterol Hepatol; 2024 Jun; 39(6):1000-1007. PubMed ID: 38425009
[TBL] [Abstract][Full Text] [Related]
97. Association Between Time to Colonoscopy After Positive Fecal Testing and Colorectal Cancer Outcomes: A Systematic Review.
Forbes N; Hilsden RJ; Martel M; Ruan Y; Dube C; Rostom A; Shorr R; Menard C; Brenner DR; Barkun AN; Heitman SJ
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1344-1354.e8. PubMed ID: 33010414
[TBL] [Abstract][Full Text] [Related]
98. The impact of driving time on participation in colorectal cancer screening with sigmoidoscopy and faecal immunochemical blood test.
Berthelsen M; Berstad P; Randel KR; Hoff G; Natvig E; Holme Ø; Botteri E
Cancer Epidemiol; 2022 Oct; 80():102244. PubMed ID: 36057171
[TBL] [Abstract][Full Text] [Related]
99. Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis.
Niedermaier T; Balavarca Y; Brenner H
Am J Gastroenterol; 2020 Jan; 115(1):56-69. PubMed ID: 31850933
[TBL] [Abstract][Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
